Updates from the AAD and AAAAI Guidelines for Managing Atopic Dermatitis

Area of Science:

• Dermatology
• Immunology
• Allergy

Background:

• The American Academy of Allergy, Asthma, and Immunology (AAAAI)/American College of Allergy, Asthma, and Immunology Joint Task Force (JTF) updated their atopic dermatitis management guidelines in 2023.
• The American Academy of Dermatology (AAD) released updated guidelines for atopic dermatitis diagnosis, assessment, and treatment in 2024.

Purpose of the Study:

• To outline key changes in the updated atopic dermatitis guidelines from the AAAAI/ACAAI JTF and AAD.
• To highlight major differences between the two sets of recommendations for atopic dermatitis management.

Main Methods:

• Comparative review of the 2023 AAAAI/ACAAI JTF and 2024 AAD guidelines for atopic dermatitis.
• Analysis of differences in treatment recommendations and comorbidity assessments.

Main Results:

• Most recommendations are similar, with minor variations in application frequency and therapy combinations.
• Key differences identified in topical PDE-4 inhibitors, topical JAK inhibitors, systemic JAK inhibitors, azathioprine, methotrexate, and mycophenolate.
• The AAD guidelines categorize evidence and certainty of comorbidity associations, while JTF provides general statements.

Conclusions:

• While largely consistent, the updated AAAAI/ACAAI JTF and AAD guidelines present distinct approaches to specific therapies and comorbidity evaluation in atopic dermatitis.
• Clinicians should be aware of these differences when managing patients with atopic dermatitis.